scholarly journals Predictive Value of Pretreatment Peripheral Neutrophil-to-Lymphocyte Ratio for Response to Neoadjuvant Chemotherapy and Breast Cancer Prognosis

2021 ◽  
Vol Volume 13 ◽  
pp. 5889-5898
Author(s):  
Xiaomin Li ◽  
Qiuwen Tan ◽  
Hongjiang Li ◽  
Xiaoqin Yang
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Predictive Value ◽  
Breast Cancer Prognosis ◽  
Neutrophil To Lymphocyte Ratio ◽  
Cancer Prognosis ◽  
Lymphocyte Ratio ◽  
Peripheral Neutrophil ◽  
Response To Neoadjuvant Chemotherapy

scholarly journals The Neutrophil to Lymphocyte Ratio Predicts the Response to Neoadjuvant Chemotherapy in Luminal B Breast Cancer

2019 ◽  
Vol 20 (7) ◽  
pp. 2209-2212 ◽  
Author(s):  
Mauricio Rivas ◽  
Francisco Acevedo ◽  
Francisco Dominguez ◽  
Hector Galindo ◽  
Mauricio Camus ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Neutrophil To Lymphocyte Ratio ◽  
Luminal B ◽  
Lymphocyte Ratio ◽  
Response To Neoadjuvant Chemotherapy

scholarly journals Systemic Immune-Inflammation Index Is Superior to Neutrophil to Lymphocyte Ratio in Prognostic Assessment of Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy

2020 ◽  
Vol 2020 ◽  
pp. 1-10
Author(s):  
Cong Jiang ◽  
Yubo Lu ◽  
Shiyuan Zhang ◽  
Yuanxi Huang
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Cancer Patients ◽  
Regression Models ◽  
Roc Analysis ◽  
Neutrophil To Lymphocyte Ratio ◽  
Breast Cancer Patients ◽  
Lymphocyte Ratio ◽  
Immune Inflammation ◽  
The Impact

Background and Methods. As a parameter integrating neutrophil (N), lymphocyte (L), and platelet (P) levels, altered systemic immune-inflammation index (SII) has been investigated in a number of malignant tumor types. Here, we explore the impact of SII in a cohort of 249 breast cancer patients receiving neoadjuvant chemotherapy (NAC), investigating the prognostic value of SII, neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR). All patients had complete follow-up data and pathological confirmation of breast cancer by a core needle biopsy prior to NAC treatment and surgery. All blood samples were obtained within one week prior to NAC. Receiver operating characteristic (ROC) analysis was used to determine the optimal cut-off value for patient classification by SII, NLR, and PLR. Associations between clinicopathological variables by SII, NLR, and PLR were determined by a chi-squared test or Fisher’s exact test. Overall survival (OS) analysis was performed using Kaplan-Meier plots, log-rank tests, and Cox proportional hazards regression models. The Z test is used to compare the prognostic ability of SII, NLR, and PLR. Results. SII, NLR, and PLR did not define patient groups with distinct clinicopathological characteristics. SII, NLR, and PLR cut-off values were 547, 2.13, and 88.23, as determined by ROC analysis; the corresponding areas under the curve (AUCs) were 0.625, 0.555, and 0.571, respectively. Cox regression models identified SII as independently associated with OS. Patients with low SII had prolonged OS (65 vs. 41 months, P = 0.017 , HR: 3.24, 95% CI: 1.23-8.55). In the Z test, the difference in AUC between SII and NLR was statistically significant ( Z = 2.721 , 95% CI: 0.0194-0.119, P = 0.0065 ). Conclusion. Our study suggests that the pretreatment SII value is significantly correlated with OS in breast cancer patients undergoing NAC and that the prognostic utility of SII is superior to that of NLR and PLR.

scholarly journals Neutrophil to lymphocyte ratio as a predictor of response to neoadjuvant chemotherapy and survival in oesophageal adenocarcinoma

BJS Open ◽  
2020 ◽  
Vol 4 (3) ◽  
pp. 416-423 ◽  
Author(s):  
A. G. M. T. Powell ◽  
C. Chin ◽  
A. H. Coxon ◽  
A. Chalishazar ◽  
A. Christian ◽  
...  
Keyword(s):  
Neoadjuvant Chemotherapy ◽  
Neutrophil To Lymphocyte Ratio ◽  
Oesophageal Adenocarcinoma ◽  
Lymphocyte Ratio ◽  
Response To Neoadjuvant Chemotherapy

Real-time ultrasound elastography for monitoring tumor response to neoadjuvant chemotherapy in primary breast cancer

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 14023-14023 ◽  
Author(s):  
H. Bando ◽  
M. Ishii ◽  
E. Tohno ◽  
E. Ueno
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Real Time ◽  
Predictive Value ◽  
Primary Breast Cancer ◽  
Tumor Response ◽  
Residual Tumor ◽  
Term Survival ◽  
Pathological Cr ◽  
Response To Neoadjuvant Chemotherapy

14023 Background: Response to neoadjuvant treatment is vital to predict a patient’s long-term survival. Precise detection of residual tumor cells after neoadjuvant chemotherapy would allow a better cosmetic results avoiding over surgery and reduce second operation due to positive margin status. Moreover, accurate prediction of pathological CR will yield no surgical intervention in certain population. Recently, a new generation of ultrasound platforms with real-time freehand elastography that enables the imaging of elasticity of the lesion by using the extended combined autocorrelation method (CAM) has become available. We are currently applying this technology to our patients with primary breast cancer in an attempt to assess response to neoadjuvant chemotherapy in comparison with MRI, conventional ultrasound and pathological findings. Methods: A total of 38 patients with primary breast cancer who underwent neoadjuvant chemotherapy and following surgical resection From May 2005 to Dec 2006 were included in this study. Board certified radiologists assessed the tumor response by MRI, US and US Elastography prior to surgery. Positive predictive value (PPV), and negative predictive value (NPV) for pathological CR (pCR) was assessed. Tsukuba Elastography score was applied for the assessment of Elastography. Results: 11/38 patients (28.9%) achieved a pCR in breast to neoadjuvant chemotherapy while no patients demonstrated progressive disease. The PPV for pCR of MRI and US was 54.5% and 36.3% respectively. The NPV of MRI and US was both 90.9%. None of the residual tumor mass with score 4 or 5 cases diagnosed by Elastography achieved pCR. When residual tumor image was detected by US, pCR was present in all 4 cases with score 1 or 2 Elatography. If the cut-off line is determined between score 3 and 4, the PPV and NPV for pCR by Elastography was 100% and 66.6% respectively. Conclusions: Elastography is easy to perform and it can provide an inexpensive, non-invasive, real-time tool for assessment of response to neoadjuvant chemotherapy among patients with primary breast cancer. In particular, Elastography might more effectively diagnose pathological CR. More patients are needed to evaluate the sensitivity and specificity of this new technology. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document